Publications and Digital Products

Monitoring the distribution and impact of opioid overdose reversal medications such as naloxone is essential to optimizing overdose prevention strategies and improving public health outcomes. This Statistical Data Profile, the first to use performance data from two SAMHSA grant programs, examines the distribution of FDA-approved opioid overdose reversal medications, including naloxone/Narcan. The Data Profile also presents the training of first responders, community organization staff and other individuals to administer the reversal medications and provide other support services.

This report presents data from DAWN using national estimates and trends of opioid-involved emergency department (ED) visits in the United States, including those involving prescription opioids, fentanyl, heroin, and opioids not otherwise specified.

This Spotlight highlights a notable finding from the evaluation of SAMHSA’s Projects for Assistance in Transition from Homelessness (PATH) program published in 2024. The PATH program is intended to reduce homelessness among persons experiencing severe mental illness or co-occurring mental illness and substance use disorders. PATH collects data on the reported residence of clients the night prior to enrolling in services. An examination of these data for FY 2019 to 2021 revealed an approximately ten-point percentage increase of PATH clients reporting being in an unsheltered situation the night prior to enrollment.

Find data on the nonuse of substances among adolescents aged 12 to 17 from the 2023 National Survey on Drug Use and Health (NSDUH). Estimates include illicit drugs, alcohol, tobacco products, and nicotine vaping.

This resource document briefly explains the three different types of CCBHCs and the pathways for becoming each. It is designed for the use of potential CCBHCs, CCBHC clinic leadership and staff, and state government officials, to support their engagement with the CCBHC model.